Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab
plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.